Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, F. E.
Right arrow Articles by Anderson, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, F. E.
Right arrow Articles by Anderson, K. C.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 July 2001, Vol. 98, No. 1, pp. 210-216

NEOPLASIA

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima, Suzanne Lentzsch, Gloria Young, Yu-Tzu Tai, Boris Lin, Klaus Podar, Deepak Gupta, Dharminder Chauhan, Steven P. Treon, Paul G. Richardson, Robert L. Schlossman, Gareth J. Morgan, George W. Muller, David I. Stirling, and Kenneth C. Anderson

From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, MA; the Celgene Corporation, Warren, NJ; and the University of Leeds, United Kingdom.

The antiangiogenic activity of thalidomide (Thal), coupled with an increase in bone marrow angiogenesis in multiple myeloma (MM), provided the rationale for the use of Thal in MM. Previously, the direct anti-MM activity of Thal and its analogues (immunomodulatory drugs, IMiDs) on MM cells was demonstrated, suggesting multiple mechanisms of action. In this study, the potential immunomodulatory effects of Thal/IMiDs in MM were examined. It was demonstrated that Thal/IMiDs do not induce T-cell proliferation alone but act as costimulators to trigger proliferation of anti-CD3-stimulated T cells from patients with MM, accompanied by an increase in interferon-gamma and IL-2 secretion. However, an increase in autologous T-cell killing of patient MM cells could not be demonstrated. A role for natural killer (NK)- and LAK-cell-mediated killing is suggested because IL-2-primed peripheral blood mononuclear cells (PBMCs) treated with Thal/IMiDs demonstrated significantly increased lysis of MM cell lines. Cold target inhibition assays suggested NK- rather than LAK-cell-mediated killing. Furthermore, this killing was not major histocompatibility complex-class restricted, and the depletion of CD56+ cells blocked the drug-induced MM cell lysis. It was significant that increased killing of patient MM cells by autologous PBMCs treated with Thal/IMiDs was also observed. Although the in vivo relevance of NK-cell-mediated MM cell killing is unknown, phenotypic analysis performed in MM patients receiving Thal therapy demonstrated an increase in CD3-CD56+ cells in patients responding to therapy. Thus in vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al.
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Blood, August 15, 2008; 112(4): 1329 - 1337.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Wu, M. Adams, T. Carter, R. Chen, G. Muller, D. Stirling, P. Schafer, and J. B. Bartlett
Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
Clin. Cancer Res., July 15, 2008; 14(14): 4650 - 4657.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, and K. Zervas
Nonthromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
Ann. Onc., May 13, 2008; (2008) mdn287v1.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Alici, T. Sutlu, B. Bjorkstrand, M. Gilljam, B. Stellan, H. Nahi, H. C. Quezada, G. Gahrton, H.-G. Ljunggren, and M. S. Dilber
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Blood, March 15, 2008; 111(6): 3155 - 3162.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Palumbo, P. Falco, P. Corradini, A. Falcone, F. Di Raimondo, N. Giuliani, C. Crippa, G. Ciccone, P. Omede, M. T. Ambrosini, et al.
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network
J. Clin. Oncol., October 1, 2007; 25(28): 4459 - 4465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. M. El-Sherbiny, J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al.
The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells
Cancer Res., September 15, 2007; 67(18): 8444 - 8449.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. D. Yildirim, M. Ayer, R. D. Kucukkaya, N. Alpay, O. Mete, M. N. Yenerel, A. S. Yavuz, and M. Nalcaci
Leukocytoclastic Vasculitis due to Thalidomide in Multiple Myeloma
Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 704 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Pellagatti, M. Jadersten, A.-M. Forsblom, H. Cattan, B. Christensson, E. K. Emanuelsson, M. Merup, L. Nilsson, J. Samuelsson, B. Sander, et al.
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients
PNAS, July 3, 2007; 104(27): 11406 - 11411.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Thornburg, R. Abonour, P. Smith, K. Knox, and H. L. Twigg III
Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide
Chest, May 1, 2007; 131(5): 1572 - 1574.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Carlo-Stella, A. Guidetti, M. Di Nicola, C. Lavazza, L. Cleris, D. Sia, P. Longoni, M. Milanesi, M. Magni, Z. Nagy, et al.
IFN-{gamma} Enhances the Antimyeloma Activity of the Fully Human Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3
Cancer Res., April 1, 2007; 67(7): 3269 - 3275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. Moutouh-de Parseval, K. Jensen-Pergakes, P. H. Schafer, R. Chen, E. Glezer, G. D. Ferguson, et al.
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
Cancer Res., January 15, 2007; 67(2): 746 - 755.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Suvannasankha, C. Fausel, B. E. Juliar, C. T. Yiannoutsos, W. B. Fisher, R. H. Ansari, L. L. Wood, G. G. Smith, L. D. Cripe, and R. Abonour
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21
Oncologist, January 1, 2007; 12(1): 99 - 106.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Richardson, E. Blood, C. S. Mitsiades, S. Jagannath, S. R. Zeldenrust, M. Alsina, R. L. Schlossman, S. V. Rajkumar, K. R. Desikan, T. Hideshima, et al.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Blood, November 15, 2006; 108(10): 3458 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. H. Chang, N. Liu, V. Klimek, H. Hassoun, A. Mazumder, S. D. Nimer, S. Jagannath, and M. V. Dhodapkar
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
Blood, July 15, 2006; 108(2): 618 - 621.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. P. von Strandmann, H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al.
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Blood, March 1, 2006; 107(5): 1955 - 1962.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
J. Clin. Oncol., January 20, 2006; 24(3): 334 - 336.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-T. Tai, X.-F. Li, L. Catley, R. Coffey, I. Breitkreutz, J. Bae, W. Song, K. Podar, T. Hideshima, D. Chauhan, et al.
Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications
Cancer Res., December 15, 2005; 65(24): 11712 - 11720.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hideshima, J. E. Bradner, D. Chauhan, and K. C. Anderson
Intracellular Protein Degradation and Its Therapeutic Implications
Clin. Cancer Res., December 15, 2005; 11(24): 8530 - 8533.
[Full Text] [PDF]

Home page
 BloodHome page
A. Chanan-Khan, K. C. Miller, K. Takeshita, A. Koryzna, K. Donohue, Z. P. Bernstein, A. Mohr, D. Klippenstein, P. Wallace, J. B. Zeldis, et al.
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL)
Blood, November 15, 2005; 106(10): 3348 - 3352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Altun, P. J. Galardy, R. Shringarpure, T. Hideshima, R. LeBlanc, K. C. Anderson, H. L. Ploegh, and B. M. Kessler
Effects of PS-341 on the Activity and Composition of Proteasomes in Multiple Myeloma Cells
Cancer Res., September 1, 2005; 65(17): 7896 - 7901.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. J. Hernandez-Ilizaliturri, N. Reddy, B. Holkova, E. Ottman, and M. S. Czuczman
Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model
Clin. Cancer Res., August 15, 2005; 11(16): 5984 - 5992.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Vacca, C. Scavelli, V. Montefusco, G. Di Pietro, A. Neri, M. Mattioli, S. Bicciato, B. Nico, D. Ribatti, F. Dammacco, et al.
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma
J. Clin. Oncol., August 10, 2005; 23(23): 5334 - 5346.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Zhang, V. Vakil, M. Braunstein, E. L. P. Smith, J. Maroney, L. Chen, K. Dai, J. R. Berenson, M. M. Hussain, U. Klueppelberg, et al.
Circulating endothelial progenitor cells in multiple myeloma: implications and significance
Blood, April 15, 2005; 105(8): 3286 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood, February 15, 2005; 105(4): 1383 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. List, S. Kurtin, D. J. Roe, A. Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, and J. B. Zeldis
Efficacy of Lenalidomide in Myelodysplastic Syndromes
N. Engl. J. Med., February 10, 2005; 352(6): 549 - 557.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. I. Rini and E. J. Small
Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma
J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, P. G. Richardson, T. Hideshima, and K. C. Anderson
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
J. Clin. Oncol., January 20, 2005; 23(3): 630 - 639.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Carbone, P. Neri, M. Mesuraca, M. T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, et al.
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
Blood, January 1, 2005; 105(1): 251 - 258.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Kaufmann, M. Raderer, S. Wohrer, A. Puspok, A. Bankier, C. Zielinski, A. Chott, and J. Drach
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
Blood, October 15, 2004; 104(8): 2269 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. K. Teo, K. H. Denny, D. I. Stirling, S. D. Thomas, S. Morseth, and A. M. Hoberman
Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring
Toxicol. Sci., October 1, 2004; 81(2): 379 - 389.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
J. Clin. Oncol., August 15, 2004; 22(16): 3212 - 3214.
[Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kumar, T. E. Witzig, and S. V. Rajkumar
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. LeBlanc, T. Hideshima, L. P. Catley, R. Shringarpure, R. Burger, N. Mitsiades, C. Mitsiades, P. Cheema, D. Chauhan, P. G. Richardson, et al.
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
Blood, March 1, 2004; 103(5): 1787 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson
Multiple Myeloma
Hematology, January 1, 2004; 2004(1): 237 - 256.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. F. List, J. Vardiman, J.-P. J. Issa, and T. M. DeWitte
Myelodysplastic Syndromes
Hematology, January 1, 2004; 2004(1): 297 - 317.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Gee, S. Makonnen, K. al-Kofahi, B. Roysam, F. Payvandi, H.-W. Man, G. W. Muller, and W. M. F. Lee
Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition
Cancer Res., December 1, 2003; 63(23): 8073 - 8078.
[Abstract] [Full Text] [PDF]